Cat. No.: DAB-0011878
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat, Hamster, Monkey |
Applications | WB, IP |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu110 of human CAMLG protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | CAMLG |
UniProt No. | P49069 |
Gene ID | 819 |
Gene Description | The calcium signal-modulating cyclophilin ligand is a multi-pass endoplasmic reticulum membrane protein that plays an important role in calcium-mediated signal transduction. The CAMLG protein was first identified in T lymphocytes as a cyclophilin B-binding protein that regulates calcium influx following T-cell receptor activation. Research studies indicate that CAMLG overexpression activates the transcription factors NFAT and NF-IL2A and leads to increased IL-2 gene transcription, providing additional evidence that CAMLG plays an important role in TCR signal transduction. CAMLG negatively regulates the non-receptor protein kinase Lck, which is critical for the thymocyte selection process. Thymocytes deficient for CAMLG fail to undergo normal development, accumulate reactive oxygen species, and exhibit increased apoptosis in response to cytotoxic stimuli. The CAMLG protein also acts as a receptor of TRC40, an ATPase that targets newly synthesized proteins in the secretory pathway to the ER membrane. CAMLG interacts with the protein insertion receptor WRB to form the TRC40 receptor complex that is responsible for insertion of tail-anchored proteins into the ER membrane. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.